Updated:
Antigenics
Antigenics is an asset manager based in Lexington; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
Overview
Antigenics (NASDAQ: AGEN) is a biotechnology company focused on developing treatments for cancers and infectious diseases.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Lexington
Corporate office
Lexington, United States
Frequently asked questions
What is Antigenics' investment strategy?
The firm invests in healthcare and technology assets, including public equities and private placements. It focuses on translational medicine and orphan drug development, but also holds a diversified portfolio of marketable securities. Strategy involves direct equity stakes and partnerships with research institutions.
What sectors does Antigenics focus on?
Sector focus is primarily healthcare, including biotechnology, orphan drugs, and medical technology. The firm has also shown interest in broader technology investments, though the exact composition of its portfolio is not publicly detailed.
Does Antigenics have any recent investment activity?
No recent investment activity is publicly documented. The firm has limited transparency regarding its current portfolio or new deals. Prior major events include the restructuring of the company following the failure of its lead cancer vaccine candidate in 2016.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: